As synthetic oligonucleotide therapeutics become validated and feasible for commercial production, manufacturers are being urged to become familiar with the Chemistry, Manufacturing, and Control (CMC) aspects of their bioprocessing workflows. The post Oligonucleotide Therapeutic Industry Readies Itself to Move to the Next Phase appeared first on GEN – Genetic Engineering and Biotechnology News.
You may also like
This common pesticide may be quietly wiping out future...
Boehringer Ingelheim’s Jascayd approved by MHRA for...
Ipsen to acquire Memo Therapeutics in deal worth more...
Macrophage Membrane-Derived Nanoparticles Shows...
Epigenomic Analysis Uncovers New AML Subgroups and...
GSK, Hansoh ADC extends survival in lung cancer study
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.